Abstract: The present invention relates to a yeast cell of the Komagataella genus comprising an orthologous promoter of a methylotrophic yeast cell or a variant thereof inducible by derepression, wherein the orthologous promoter is an orthologous formate dehydrogenase (FMD) promoter of a methylotrophic yeast cell.

Abstract: The invention relates to polypeptides having peroxygenase activity and compositions comprising such polypeptides. The invention also relates to improved methods of producing such polypeptides in yeasts.

Abstract: The present invention relates to a process for biocatalytic amidation of non-protected amino acids comprising the step of contacting a non-protected amino acid with an ammonia source in the presence of an organic solvent and an enzyme.

Abstract: The present invention relates to a yeast cell of the Komagataella genus comprising an orthologous promoter of a methylotrophic yeast cell or a variant thereof inducible by derepression, wherein the orthologous promoter is an orthologous formate dehydrogenase (FMD) promoter of a methylotrophic yeast cell.

Abstract: An episomal plasmid comprising a gene of interest (GOI) and an autonomously replicating sequence (ARS) which is not operably linked to the GOI, which ARS comprises or consists of a nucleotide sequence identified as any of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6-11, or a functionally active variant of any of the foregoing which is characterized by at least 60% sequence identity thereto.

Abstract: The present invention relates to an optimized metabolic pathway design in P. pastoris. In particular, to a recombinant polycistronic expression construct for stable expression of multiple genes of interest in a yeast cell, preferably in P. pastoris.

Abstract: The present application provides novel polypeptides having xylanase activity and the respective nucleic acid sequences encoding those polypeptides as well as vectors comprising these nucleic acid sequences and host cells transformed by these vectors. In addition the present invention provides a method for producing these polypeptides and a composition comprising the inventive polypeptides.

Abstract: An episomal plasmid comprising a gene of interest (GOI) and an autonomously replicating sequence (ARS) which is not operably linked to the GOI, which ARS comprises or consists of a nucleotide sequence identified as any of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6-11, or a functionally active variant of any of the foregoing which is characterized by at least 60% sequence identity thereto.

Abstract: The present invention relates to a nucleic acid construct comprising a nucleic acid molecule encoding a protein involved in the biosynthesis of a terpenoid or a precursor thereof, wherein said nucleic acid molecule is operably linked to a derepressible promoter.

Abstract: The invention refers to a library of bidirectional expression cassettes or expression vectors comprising a repertoire of bidirectional promoter sequences, each expression cassette comprising a promoter sequence operably linked to a first gene in one direction, and operably linked to an oppositely oriented second gene in the other direction which is different from the first gene, and bidirectional Pichia pastoris or CHO cells promoter sequences. The invention further refers to a method of screening or selecting a bidirectional promoter suitable for expressing at least two GOI in a host cell and a kit comprising a) an expression cassette consisting of the first and second genes and a stuffer sequence separating them, which stuffer sequence comprises a recognition site for a type IIS restriction enzyme at both ends; b) the type IIS restriction enzyme; c) and a repertoire of promoter, preferably a promoter library including bidirectional promoters.

Abstract: The present application provides novel polypeptides having xylanase activity and the respective nucleic acid sequences encoding those polypeptides as well as vectors comprising these nucleic acid sequences and host cells transformed by these vectors. In addition the present invention provides a method for producing these polypeptides and a composition comprising the inventive polypeptides.

Abstract: The present invention relates to an optimized metabolic pathway design in P. pastoris. In particular, to a recombinant polycistronic expression construct for stable expression of multiple genes of interest in a yeast cell, preferably in P. pastoris.

Abstract: Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3.

Abstract: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (?784 to ?719), nucleotides 170 to 191 (?784 to ?763), nucleotides 192 to 213 (?762 to ?741), nucleotides 192 to 210 (?762 to ?744), nucleotides 207 to 209 (?747 to ?745), nucleotides 214 to 235 (?740 to ?719), nucleotides 304 to 350 (?650 to ?604), nucleotides 364 to 393 (?590 to ?561), nucleotides 434 to 508 (?520 to ?446), nucleotides 509 to 551 (?445 to ?403), nucleotides 552 to 560 (?402 to ?394), nucleotides 585 to 617 (?369 to ?337), nucleotides 621 to 660 (?333 to ?294), nucleotides 625 to 683 (?329 to ?271), nucleotides 736 to 741 (?218 to ?213), nucleotides 737 to 738 (?217 to ?216), nucleotides 726 to 755 (?228 to ?199), nucleotides 784 to 800 (?170 to ?154) or nucleotides 823 to 861 (?131 to ?93) of Seq ID No.

Abstract: A new process for enhancing the hydrophilicity of the surface of a polyolefin or polyolefin copolymer article is characterized in that the surface is treated with an enzyme selected from oxidoreductases, especially of the cytochrome P450 family or enzymes classified as EC 1.13 or EC 1.14. The process is especially useful for the treatment of polypropylene films, fibres, or fabrics, inter alia for use in sanitary articles, threads, yarns, fabrics, textiles, garments, technical or household articles, printed or dyed cover films or packaging films.

Abstract: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (?784 to ?719), nucleotides 170 to 191 (?784 to ?763), nucleotides 192 to 213 (?762 to ?741), nucleotides 192 to 210 (?762 to ?744), nucleotides 207 to 209 (?747 to ?745), nucleotides 214 to 235 (?740 to ?719), nucleotides 304 to 350 (?650 to ?604), nucleotides 364 to 393 (?590 to ?561), nucleotides 434 to 508 (?520 to ?446), nucleotides 509 to 551 (?445 to ?403), nucleotides 552 to 560 (?402 to ?394), nucleotides 585 to 617 (?369 to ?337), nucleotides 621 to 660 (?333 to ?294), nucleotides 625 to 683 (?329 to ?271), nucleotides 736 to 741 (?218 to ?213), nucleotides 737 to 738 (?217 to ?216), nucleotides 726 to 755 (?228 to ?199), nucleotides 784 to 800 (?170 to ?154) or nucleotides 823 to 861 (?131 to ?93) of Seq ID No.

Abstract: The present invention relates to the use of recombinant heme-containing horseradish peroxidase isoenzyme with improved technological properties such as altered glycosylation, improved catalytic properties or improved stability and different ranges of pH optima and improved surface interactions in the treatment of waste water.

Abstract: The invention refers to a library of bidirectional expression cassettes or expression vectors comprising a repertoire of bidirectional promoter sequences, each expression cassette comprising a promoter sequence operably linked to a first gene in one direction, and operably linked to an oppositely oriented second gene in the other direction which is different from the first gene, and bidirectional Pichia pastoris or CHO cells promoter sequences. The invention further refers to a method of screening or selecting a bidirectional promoter suitable for expressing at least two GOI in a host cell and a kit comprising a) an expression cassette consisting of the first and second genes and a stuffer sequence separating them, which stuffer sequence comprises a recognition site for a type IIS restriction enzyme at both ends; b) the type IIS restriction enzyme; c) and a repertoire of promoter, preferably a promoter library including bidirectional promoters.

Abstract: The present invention relates to recombinant heme-containing horseradish peroxidase isoenzymes with improved properties. In particular, the present invention relates to a plant enzyme kit comprising recombinant peroxidase isoenzymes, preferably horseradish peroxidase isoenzymes.

Abstract: Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3.